Lilly To Discontinue Two Humulins - Ultralente and Lente - By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says declining commercial demand is the reason for its decision to discontinue production of the longer-acting Humulins as well as Iletin insulins. Lilly sends out "Dear Doctor" letters and will help transition patients to the company's other insulin products through coupons for free samples.